Clinical Trials
13 trialsNCT05295589 2023-09-26
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT04943627 2022-10-05
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Agenus Inc.
Phase 3 Withdrawn
NCT03193463 2019-03-01
Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT00109798 2017-09-19
Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
The Methodist Hospital Research Institute
Phase NA Withdrawn
NCT01736800 2017-09-19
Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT00980551 2017-03-03
RELRB1
Children's Hospital Medical Center, Cincinnati
Phase NA Withdrawn
NCT02348398 2016-08-16
Phase II Study of Pazopanib and Topotecan in Cervical Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00682279 2015-04-17
A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Withdrawn
NCT01795430 2015-01-09
Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma
City of Hope Medical Center
Phase NA Withdrawn
NCT00006374 2014-01-15
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00084565 2013-07-10
Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT00389766 2013-07-10
High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00334867 2013-06-28
Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma
Children's Oncology Group
Phase 3 Withdrawn